Showing 1 - 10 of 34 Other
Multicenter, Registry Study of Avance® Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair

Status: Enrolling

Investigator: Warren Ellsworth

Study Coordinator: Valentina Villarroel

Phone: 346.238.4384

This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label. ... Read more >

A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination with Obeticholic Acid in Subjects with Primary Biliary Cholangitis

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Beatriz Efron

Phone: 713.363.8890

Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC). ... Read more >

A Phase 2a, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

Status: Open Not Enrolling

Investigator: Michael Klebuc

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

This study involves the use of an Investigational Product called NTX-001. It is a product used in the repair of nerve injuries. It is used in the operating room. The main purposes of this study are to 1) see how safe NTX-001 is when used in nerv ... Read more >

A Prospective Study Evaluating the Clinical Outcomes of Ventral Hernias treated Robotically with OviTex® Reinforced Tissue Matrix

Status: Open Not Enrolling

Investigator: Nabil Tariq

Study Coordinator: Nicole Hinton

Phone: 281.755.0796

This study is designed to evaluate the post-operative complications and re-herniations following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.</ ... Read more >

A randomized, double-blind, placebo controlled, dosefinding study to assess the efficacy and safety of SAR443122 in adult patients with moderate to severe ulcerative colitis

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for furt ... Read more >

A randomized, double-blind, placebo-controlled, multicenter, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2/fibrosis 3 stage of liver fibrosis

Status: Enrolling

Investigator: David Victor

Study Coordinator: Beatriz Efron

Phone: 713.363.8890

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Rosa Barrosa da Costa

Phone: 713.441.5660

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period. ... Read more >

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension (TROPOS Study)

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Cassidy Smith

Phone: 713.441.4106

Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy. The study is divided into ... Read more >

ABTECT - Maintenance

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequa ... Read more >

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequat ... Read more >

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension (ASCENT Study) LTI-401

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Nelson Villasmil Hernandez

Phone: 832.970.3187

Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability ofLIQ861 in subjects who have WHO Group 1 & 3 PH. Cohort A will include approximately 60 subjects who have WHO Group 3 Pulmonary Hypertension assoc ... Read more >

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice. ... Read more >

An Open-label, Phase II, Pre-operative Study of Atezolizumab plus Bevacizumab for Resectable Hepatocellular Carcinoma

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator: Beatriz Efron

Phone: 713.363.8890

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for ... Read more >

Corrona Inflammatory Bowel Disease (IBD) Registry

Status: Enrolling

Investigator: Bincy Abraham

Study Coordinator: Mayyadah Al-Sabbagh

Phone: 346.238.0024

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >

DeciPHer-ILD: a Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Status: Open Not Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

The purpose of this study is to observe and capture demographic characteristics, treatment patterns, and clinical outcomes of interest for patients with PH-ILD to further clinical understanding of the epidemiological landscape and outcomes of th ... Read more >

Effi cacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease (ENHANCE-CD)

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance th ... Read more >

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry (IPF/ILD-PRO)

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Jennifer Lee

Phone: 713.363.7537

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >

N/A

Status: Enrolling

Investigator: Sunil Dacha

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

The goal of this research is to learn about pyloric sphincter characteristics (measure sphincter pressure, area, and elasticity) in both patients with gastroparesis and without gastroparesis using the endoscopic functional lumen imaging probe (E ... Read more >

NMDA Receptor in Psychosis: Specific Auto-Antibodies

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator:

Phone:

Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N- ... Read more >

Ocrelizumab for Psychosis by Autoimmunity (OPA)

Status: Enrolling

Investigator: Joseph Masdeu

Study Coordinator: Jeffrey Ling

Phone: 713.363.7753

Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to at ... Read more >

Phase 2, Randomized Double-Blind Double-Dummy Placebo-Controlled Study Testing the Safety & Efficacy of Semaglutide, & the Fixed-Dose Combination of Cilofexor & Firsocostat, Alone & in Combination, in Subjects with Compensated Cirrhosis (F4) due to NASH

Status: Open Not Enrolling

Investigator: David Victor

Study Coordinator: Beatriz Efron

Phone: 713.363.8890

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steat ... Read more >

Phase III, Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate Tozorakimab in Participants with COPD with a History of COPD Exacerbations (MIRANDA)

Status: Open Not Enrolling

Investigator: Rodney Folz

Study Coordinator: Mayyadah al-Sabbagh

Phone: 346.238.0024

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab300 mg administered subcutaneously (SC) every 2 weeks (Q2W) in adult participants with symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a histo ... Read more >

Pulmonary Hypertension Association Registry (PHAR)

Status: Open Not Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Royanne Holy

Phone: 713.363.7536

The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in part ... Read more >

Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)

Status: Enrolling

Investigator: Sandeep Sahay

Study Coordinator: Herpreet Sandhu

Phone: 713.441.5660

Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). In this study, subjects will undergo a broad ran ... Read more >

Randomized Controlled Trial Comparing NEUROMARK System to Sham Control in Patients With Chronic Rhinitis

Status: Enrolling

Investigator: Masayoshi Takashima

Study Coordinator: Tariq Syed

Phone: 346.238.6466

The NEUROMARK RCT Study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial. ... Read more >

Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.

Status: Enrolling

Investigator: Masayoshi Takashima

Study Coordinator: Tariq Syed

Phone: 346.238.6466

The purpose of this study is to determine the safety and effectiveness of CYR-064 in a randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR064. The study will take approximately 32 weeks which will ... Read more >

REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study

Status: Enrolling

Investigator: Christopher Fan

Study Coordinator: Zinah Rasheed

Phone: 713.363.7536

This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe ... Read more >

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease (Target CD)

Status: Open Not Enrolling

Investigator: Malcolm Irani

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and ... Read more >

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension standard of care or PAH-specific background therapy in subjects with World Health Organization Group 1 PAH

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Ana Lucia Varon Ocampo

Phone: 713.441.7182

Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific backgro ... Read more >

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag

Status: Enrolling

Investigator: Zeenat Safdar

Study Coordinator: Ana Lucia Varon Ocampo

Phone: 713.441.7182

Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. S ... Read more >

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Status: Enrolling

Investigator: William Ondo

Study Coordinator: Daniel Arnaud Dominguez

Phone: 346.356.3635

This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 ... Read more >

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Status: Open Not Enrolling

Investigator: Bincy Abraham

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate ... Read more >

X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP)

Status: Open Not Enrolling

Investigator: Laila Tabatabai

Study Coordinator: Melissa Whipple

Phone: 713.441.3247

The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of buro ... Read more >